TOUCH CMC 1 Prosthesis
Keri Medical SA · Decision date Sep 5, 2025
What did the FDA approve?
FDA records P240020/S001 as a supplement to PMA P240020, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Sep 5, 2025.
FDA approval order statement
Approval of the protocol for the post-approval study (PAS), Continued Long-Term Follow-up Study. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240020.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Orthopedic
- Decision date
- Sep 5, 2025
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P240020/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Keri Medical SA
- Product code
- SFA
- Decision code
- APPR
- Decision date
- Sep 5, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, finger, semi-constrained, metal/polymer.
- Applicant
- Keri Medical SA
- Product code
- SFA
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P240020/S001 received
Application receipt date recorded by FDA.
P240020/S002 · Related supplement
TOUCH CMC 1 Prosthesis
P240020/S001 · FDA decision
Normal 180 Day Track No User Fee
P240020/S003 · Related supplement
TOUCH CMC 1 Prosthesis
P240020/S005 · Related supplement
TOUCH CMC 1 Prosthesis
P240020/S004 · Related supplement
TOUCH CMC 1 Prosthesis
P240020/S006 · Related supplement
TOUCH CMC 1 Prosthesis
Timeline entries are records held by MedtechLedger for P240020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
TOUCH CMC 1 ProsthesisP240020/S002 | Keri Medical SA | PMA supplement | Sep 5, 2025 | FDA |
TOUCH CMC 1 ProsthesisP240020/S003 | Keri Medical SA | PMA supplement | Dec 17, 2025 | FDA |
TOUCH CMC 1 ProsthesisP240020/S005 | Keri Medical SA | PMA supplement | Apr 13, 2026 | FDA |
TOUCH CMC 1 ProsthesisP240020/S004 | Keri Medical SA | PMA supplement | May 12, 2026 | FDA |
TOUCH CMC 1 ProsthesisP240020/S006 | Keri Medical SA | PMA supplement | Jun 24, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Keri Medical SA
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Chemin Du Pre-Fleuri 5, 1228 Plan-Les-Ouates
Sources and methodology
- Original FDA record: P240020/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



